Indian drugmaker Dr Reddy’s Laboratories Ltd. is planning to launch a generic version of Novo Nordisk A/S’s Ozempic in March after the drug’s patent expiry, becoming one of the first firms to capture the gold rush for the therapy in the South Asian country.

Dr Reddy’s will sell at “competitive pricing” to ensure affordability, M. V. Ramana, its chief executive officer for Branded Markets, told reporters Wednesday. The pricing will also depend on how peers price their product.